Jpmorgan Chase & CO Novo Cure LTD Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Novo Cure LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 217,657 shares of NVCR stock, worth $4.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
217,657
Previous 367,702 40.81%
Holding current value
$4.16 Million
Previous $11 Million 64.61%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$17.82 - $30.19 $2.67 Million - $4.53 Million
-150,045 Reduced 40.81%
217,657 $3.88 Million
Q4 2024

Feb 12, 2025
SELL
$14.54 - $33.41 $672,024 - $1.54 Million
-46,219 Reduced 11.17%
367,702 $11 Million
Q3 2024

Dec 26, 2024
BUY
$15.61 - $23.34 $4.53 Million - $6.77 Million
290,265 Added 234.74%
413,921 $6.47 Million
Q3 2024

Nov 08, 2024
BUY
$15.61 - $23.34 $4.53 Million - $6.77 Million
290,265 Added 234.74%
413,921 $6.47 Million
Q2 2024

Dec 26, 2024
SELL
$11.83 - $24.05 $3.43 Million - $6.98 Million
-290,265 Reduced 70.13%
123,656 $2.12 Million
Q2 2024

Aug 12, 2024
BUY
$11.83 - $24.05 $172,351 - $350,384
14,569 Added 13.36%
123,656 $2.12 Million
Q1 2024

Dec 26, 2024
SELL
$12.42 - $17.29 $3.79 Million - $5.27 Million
-304,834 Reduced 73.65%
109,087 $1.71 Million
Q1 2024

May 10, 2024
SELL
$12.42 - $17.29 $487,485 - $678,632
-39,250 Reduced 26.46%
109,087 $1.71 Million
Q4 2023

Dec 26, 2024
SELL
$11.13 - $15.78 $2.96 Million - $4.19 Million
-265,584 Reduced 64.16%
148,337 $2.21 Million
Q4 2023

Feb 12, 2024
SELL
$11.13 - $15.78 $2.4 Million - $3.4 Million
-215,472 Reduced 59.23%
148,337 $2.21 Million
Q3 2023

Nov 14, 2023
BUY
$16.15 - $42.35 $3.73 Million - $9.77 Million
230,748 Added 173.42%
363,809 $5.88 Million
Q2 2023

Aug 11, 2023
SELL
$40.29 - $82.51 $7.73 Million - $15.8 Million
-191,883 Reduced 59.05%
133,061 $5.52 Million
Q1 2023

May 18, 2023
BUY
$56.44 - $118.81 $210,182 - $442,448
3,724 Added 1.16%
324,944 $19.5 Million
Q1 2023

May 11, 2023
BUY
$56.44 - $118.81 $587,879 - $1.24 Million
10,416 Added 3.35%
321,220 $19.3 Million
Q4 2022

Feb 13, 2023
BUY
$63.98 - $85.37 $6.1 Million - $8.14 Million
95,343 Added 44.25%
310,804 $22.8 Million
Q3 2022

Nov 14, 2022
SELL
$67.99 - $89.57 $384,823 - $506,966
-5,660 Reduced 2.56%
215,461 $16.4 Million
Q2 2022

Aug 11, 2022
SELL
$56.6 - $89.9 $5.37 Million - $8.52 Million
-94,808 Reduced 30.01%
221,121 $15.4 Million
Q1 2022

May 11, 2022
BUY
$60.15 - $84.52 $4.49 Million - $6.31 Million
74,642 Added 30.93%
315,929 $26.2 Million
Q4 2021

Feb 10, 2022
BUY
$75.08 - $121.99 $15.1 Million - $24.5 Million
200,864 Added 496.91%
241,287 $18.1 Million
Q3 2021

Nov 12, 2021
BUY
$116.17 - $194.55 $4.7 Million - $7.86 Million
40,423 New
40,423 $4.7 Million

Others Institutions Holding NVCR

# of Institutions
266
Shares Held
79.4M
Call Options Held
970K
Put Options Held
118K
View Full List

About NovoCure Ltd

NVCR Quotes by TradingView
  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.01B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email